10月 25, 2022
FDA Accepts NMP's Clinical Trial Application for Development of NMK89 as Imaging Agent for Cancer Diagnosis
20221025_NewsRelease_Web_NMK89_eng.pdf373.97 KB
7月 6, 2022
Nihon Medi-Physics and PeptiDream Agree to Conclude Strategic Alliance for the Discovery & Development of Peptide-based Theranostics
220706_newsrelease_conclude_alliance.pdf_eng.pdf302.51 KB
4月 5, 2022
Nihon Medi-Physics Attains World’s First Manufacturing of Actinium-225 with Cyclotron on Production Scale for Investigational Drugs - Core Material Used for Targeted Alpha Therapy (TAT) Expected to Be Novel Treatment for Cancer -
20220405_newsrelease_ac225_e.pdf716.66 KB
6月 15, 2020
Nihon Medi-Physics and Global Medical Solutions Announce Strategic Partnership in Nuclear Medicine Markets in Asia and Oceania
ENG_20200615_Press Release_GMS.pdf841.44 KB
10月 11, 2019
Nihon Medi-Physics Launches In-house Production of Molybdenum-99
Press Release_191011Molybdenum-99.pdf262.55 KB
10月 11, 2019
Nihon Medi-Physics Accelerates “Theranostics” Development
Press Release_191011_Theranostics.pdf458.74 KB
7月 3, 2019
Nihon Medi-Physics and Combinostics Enter into an Exclusive Agreement to Develop and Market Software Diagnosing Dementia
20190703.pdf610.71 KB
6月 25, 2019
DuChemBio and Nihon Medi-Physics sign joint Development and Distribution Agreement to Develop and Commercialize FACBC
20190625.pdf720.06 KB
3月 26, 2019
Nihon Medi-Physics' Strategic Move for Contribution to Cancer Treatment
20190326.pdf578.87 KB
1月 18, 2019
Nihon Medi-Physics & Yantai Dongcheng Pharmaceutical Group Announce Strategic Partnership for Enhancing Presence in Chinese Nuclear Medicine Market
20190118.pdf579.64 KB